BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38664760)

  • 1. Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review.
    Guo Y; Pan Y; Wan J; Gong B; Li Y; Kan X; Zheng C
    BMC Cancer; 2024 Apr; 24(1):523. PubMed ID: 38664760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
    Hou B; Wang P; Liu T; Chen S; Li T; Zhang S; Tao H; Li X; Hu Y
    Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101748. PubMed ID: 34182184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
    Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
    JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials.
    Sorich MJ; Rowland A; Karapetis CS; Hopkins AM
    J Thorac Oncol; 2019 Aug; 14(8):1440-1446. PubMed ID: 30999110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
    Carril-Ajuria L; Lavaud P; Dalban C; Negrier S; Gravis G; Motzer RJ; Chevreau C; Tannir NM; Oudard S; McDermott DF; Laguerre B; Hammers HJ; Barthelemy P; Plimack ER; Borchiellini D; Gross-Goupil M; Jiang R; Lee CW; de Silva H; Rini BI; Escudier B; Albigès L
    Eur J Cancer; 2024 Jun; 204():114048. PubMed ID: 38653033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis.
    Liu H; Yang XL; Yang XY; Dong ZR; Chen ZQ; Hong JG; Li T
    Front Oncol; 2021; 11():691002. PubMed ID: 34631525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma.
    Sun T; Guo Y; Sun B; Chen L; Ren Y; Zhu L; Zhang L; Liu Y; Zheng C
    Eur J Med Res; 2023 Jul; 28(1):225. PubMed ID: 37408056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
    Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A
    Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
    Riudavets M; Auclin E; Mosteiro M; Dempsey N; Majem M; Prelaj A; López-Castro R; Bosch-Barrera J; Pilotto S; Escalera E; Tagliamento M; Mosquera J; Zalcman G; Aboubakar Nana F; Ponce S; Albarrán-Artahona V; Dal Maso A; Spotti M; Mielgo X; Mussat E; Reyes R; Benítez JC; Lupinacci L; Duchemann B; De Giglio A; Blaquier JB; Audigier-Valette C; Scheffler M; Nadal E; Lopes G; Signorelli D; Garcia-Campelo R; Menis J; Bluthgen V; Campayo M; Recondo G; Besse B; Mezquita L; Planchard D
    Clin Lung Cancer; 2024 May; 25(3):233-243.e8. PubMed ID: 38105153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.
    Wang W; Huang Z; Yu Z; Zhuang W; Zheng W; Cai Z; Shi L; Yu X; Lou G; Hong W; Zhang Y; Chen M; Song Z
    Front Oncol; 2020; 10():572853. PubMed ID: 33163403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
    Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
    Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer.
    Xiong A; Xu J; Wang S; Zhong R; Lu J; Chu T; Zhang W; Li Y; Zheng X; Han B; Nie W; Zhong H; Zhang X
    Front Immunol; 2023; 14():1173025. PubMed ID: 37304273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer.
    Zhao Q; Li B; Xu Y; Wang S; Zou B; Yu J; Wang L
    Cancer Med; 2021 Sep; 10(18):6291-6303. PubMed ID: 34390218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab.
    Veccia A; Sforza V; Vattemi E; Inno A; Kinspergher S; Dipasquale M; Gori S; Morabito A; Baldi I; Caffo O
    Immunotherapy; 2021 Sep; 13(13):1093-1103. PubMed ID: 34190578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors.
    Meyers DE; Stukalin I; Vallerand IA; Lewinson RT; Suo A; Dean M; North S; Pabani A; Cheng T; Heng DYC; Bebb DG; Morris DG
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31684111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma.
    Parent P; Auclin E; Patrikidou A; Mezquita L; Martínez Chanzá N; Dumont C; Rodriguez-Vida A; Llacer C; Lozano R; Ratta R; Merseburger AS; Sternberg CN; Baciarello G; Colomba E; Fuerea A; Besse B; Loriot Y; Lavaud P
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.